Genflow Biosciences plc (LON:GENF)

Market Cap	12.32M +229.2%
Revenue (ttm)	585.61K +82.7%
Net Income	-1.42M
EPS	-0.00
Shares Out	566.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,577,554
Open	2.189
Previous Close	2.150
Day's Range	2.100 - 2.250
52-Week Range	0.756 - 3.120
Beta	2.28
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 28, 2026

About Genflow Biosciences

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunct...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: GENF

Financial Performance

In 2025, Genflow Biosciences's revenue was 585,607, an increase of 82.73% compared to the previous year's 320,471. Losses were -1.42 million, -10.69% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error